Lee Yi-Wei, Chen Eve, Chuang Yi-Ting, Ma Wei-Li, Wu Shang-Ju
Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; University of California, Davis, Davis, CA, USA.
J Formos Med Assoc. 2025 May;124(5):467-470. doi: 10.1016/j.jfma.2024.12.002. Epub 2024 Dec 7.
People living with HIV (PLWH) have an increased risk of developing cancers, especially hematologic malignancies (HM). Hematopoietic stem cell transplantation (HSCT) has been an important treatment modality for patients with HM. However, the experience of HSCT in PLWH with HM remains limited in Asia. Therefore, we describe a case series of PLWH treated with HSCT in Taiwan. In these PLWH patients, HSCT procedures, either autologous (auto-HSCT) or allogeneic (allo-HSCT), were feasible with acute toxicity profiles comparable to those in non-HIV patients. However, auto-HSCT seemed unable to lead toward durable remission in PLWH with relapsed/refractory lymphoma, implicating that allo-HSCT might warrant early considerations for consolidation purposes in this distinct patient group.
人类免疫缺陷病毒感染者（PLWH）患癌症的风险增加，尤其是血液系统恶性肿瘤（HM）。造血干细胞移植（HSCT）一直是HM患者的重要治疗方式。然而，在亚洲，PLWH合并HM接受HSCT的经验仍然有限。因此，我们描述了台湾地区接受HSCT治疗的PLWH病例系列。在这些PLWH患者中，HSCT程序，无论是自体（auto-HSCT）还是异体（allo-HSCT），都是可行的，急性毒性反应与非HIV患者相当。然而，auto-HSCT似乎无法使复发/难治性淋巴瘤的PLWH实现持久缓解，这意味着allo-HSCT可能值得在这一特殊患者群体中作为巩固治疗的早期考虑。
